Evidence map›Paper›PMID 37582832›Full record

ArticleCell death discovery2023

Nanoparticles carrying paclitaxel and anti-miR-221 for breast cancer therapy triggered by ultrasound.

Libo Zhang, Zhen Ren, Jinhui Lü, Xinhai Mo, Jie Lin, Ya Li, Wenjing Ma, Pengfei Liu, Yajing Shen, Qian Zhao and 4 more

Open access · goldAbstract read
In one paragraph

Article in Cell death discovery, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
2.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 25 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Tumor-Associated Macrophage in Breast Tumor Microenvironment.International journal of molecular sciences · 2025
    Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Anticancer Effect of Mycotoxins FromInternational journal of microbiology · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Libo Zhang *Department of Ultrasound Medicine, Shanghai East Hospital, Nanjing Medical University, 150 Jimo Road, Shanghai, China.
Zhen Ren *Research Center for Translational Medicine, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China.
Jinhui LüResearch Center for Translational Medicine, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China.
Xinhai MoResearch Center for Translational Medicine, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China.
Jie LinResearch Center for Translational Medicine, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China.
Ya LiResearch Center for Translational Medicine, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China.
Wenjing MaResearch Center for Translational Medicine, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China.
Pengfei LiuResearch Center for Translational Medicine, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China.
Yajing ShenResearch Center for Translational Medicine, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China.
Qian ZhaoResearch Center for Translational Medicine, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China.ORCID http://orcid.org/0000-0003-1641-7137
Lu QianResearch Center for Translational Medicine, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China.
Xiaoxin ChengSchool of Basic Medical Sciences, Dalian Medical University, Dalian, China.
Zuoren YuDepartment of Ultrasound Medicine, Shanghai East Hospital, Nanjing Medical University, 150 Jimo Road, Shanghai, China. Zuoren.yu@tongji.edu.cn.ORCID http://orcid.org/0000-0003-4196-9662
Bo ZhangResearch Center for Translational Medicine, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China. zhangbo2016@tongji.edu.cn.ORCID http://orcid.org/0000-0002-0607-6044
Shanghai East Hospital · CNDalian Medical University · CNTongji University · CN

Funding

National Natural Science Foundation of China (National Science Foundation of China) 81871361
6 · The paper itself

Abstract

Nanomaterials have been well demonstrated to have the potential to be used for tumor cell-targeted drug delivery. Targeted inhibition of miR-221 was proved to promote the sensitivity of triple genitive breast cancer (TNBC) cells to chemo-drugs. In order to improve the chemotherapeutic effect in TNBC, herein, we developed a novel kind of nanoparticles shelled with PLGA and loaded with perfluoropentane (PFP), paclitaxel (PTX), and anti-miR-221 inhibitor, which was named PANP. Ultrasound-triggered vaporization of PFP in PANPs was utilized for real-time imaging track of the nanoparticles in vivo. In addition, macrophages were applied for the internalization of PANPs to form RAW-PANP with strong chemotaxis to accumulate around cancer cells. Nanoparticles with different contents did not cause M2 polarization compared with the control group but caused polarization toward M1. We compared the inherent tumor-homing behavior of macrophages containing different contents with that of normal macrophages and no significant abnormalities were observed. After injection into the tumor-burden mice, RAW-PANPs showed enrichment within tumor tissues. Upon the ultrasound cavitation-triggered burst, PTX was released in the tumor. Meanwhile, the release of anti-miR-221 improved the sensitivity of tumor cells to PTX. As a result, RAW-PANPs showed high efficiency in suppressing TNBC cell proliferation in vitro and inhibiting tumor growth and progression in vivo. The treatments did not induce liver, heart, or kidney injury. In conclusion, the current study not only developed a macrophage-carried, ultrasound-triggered, cancer cell-targeted chemotherapeutic system, but also demonstrated a miRNA-based technique to promote drug sensitivity of cancer cells, which holds strong potential to treat patients with TNBC, especially for those suffering drug-resistance. The innovation of this study is to use macrophages to deliver nanoparticles to the tumors and then use ultrasound locally to burst the nanoparticles to release the miRNA and PTX.

Identifiers

PMID37582832
PMCPMC10427607
OpenAlexW4385839766

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.